OncoTargets and Therapy (Dec 2019)
Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells
Abstract
Xiaoxu Ge,1–4,* Yamei Zhao,1–4,* Chao Chen,1–4 Jian Wang,1–4 Lifeng Sun1–4 1Department of Colorectal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, People’s Republic of China; 3Key Laboratory of Molecular Biology in Medical Sciences, Hangzhou, People’s Republic of China; 4The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lifeng SunDepartment of Colorectal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiefang Road 88, Hangzhou, Zhejiang 310009, People’s Republic of ChinaTel +86-571-87783586Email [email protected]: Tumor-associated regulatory T cells (Tregs) are important effectors in the tumor microenvironment (TME), acting as accomplices in the promotion of tumor progression. Currently, the importance of removing the immunosuppressive activity in the TME has received its due attention, and Tregs have been focused on. The cytokine-receptor axes are among the essential signaling pathways in immunocytes, and tumor-associated Tregs are no exception. Therefore, manipulating cytokine-receptor pathways may be a promising effective strategy for treating various malignancies. Here, we summarize the classification, immunosuppressive mechanisms, existing immunotherapies, and potential biomarkers related to tumor-infiltrating Tregs to guide the development of effective cancer immunotherapies.Keywords: Tregs, immune suppression, chemokine receptors, biomarkers, cancer immunotherapies
